Leerink Swann Weighs in on Aurinia Pharmaceuticals Inc’s Q2 2017 Earnings (AUPH)
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Stock analysts at Leerink Swann lowered their Q2 2017 EPS estimates for Aurinia Pharmaceuticals in a research report issued on Monday. Leerink Swann analyst J. Schwartz now expects that the biotechnology company will earn ($0.13) per share for the quarter, down from their previous estimate of ($0.11). Leerink Swann currently has a “Outperform” rating and a $11.00 price objective on the stock. Leerink Swann also issued estimates for Aurinia Pharmaceuticals’ Q3 2017 earnings at ($0.14) EPS, Q4 2017 earnings at ($0.15) EPS, FY2017 earnings at ($0.42) EPS and FY2018 earnings at ($0.70) EPS.
Several other analysts also recently weighed in on the company. FBR & Co reaffirmed an “outperform” rating and set a $11.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, March 22nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, April 21st. Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, March 20th. HC Wainwright lifted their target price on Aurinia Pharmaceuticals from $8.00 to $12.00 and gave the company a “positive” rating in a research note on Friday, March 3rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, March 3rd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Aurinia Pharmaceuticals has a consensus rating of “Buy” and an average price target of $9.64.
TRADEMARK VIOLATION NOTICE: “Leerink Swann Weighs in on Aurinia Pharmaceuticals Inc’s Q2 2017 Earnings (AUPH)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/18/leerink-swann-weighs-in-on-aurinia-pharmaceuticals-incs-q2-2017-earnings-auph.html.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 7.06 on Thursday. Aurinia Pharmaceuticals has a one year low of $1.74 and a one year high of $10.54. The company’s 50-day moving average price is $7.10 and its 200-day moving average price is $4.64. The firm’s market cap is $377.20 million.
Aurinia Pharmaceuticals (NASDAQ:AUPH) last announced its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 109.61% and a negative net margin of 9,512.50%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million.
Several hedge funds have recently bought and sold shares of AUPH. Jane Street Group LLC purchased a new stake in Aurinia Pharmaceuticals during the first quarter worth approximately $155,000. Geode Capital Management LLC purchased a new stake in Aurinia Pharmaceuticals during the first quarter worth approximately $187,000. Oxford Asset Management purchased a new stake in Aurinia Pharmaceuticals during the fourth quarter worth approximately $211,000. Two Sigma Securities LLC purchased a new stake in Aurinia Pharmaceuticals during the first quarter worth approximately $240,000. Finally, TD Asset Management Inc. purchased a new stake in Aurinia Pharmaceuticals during the first quarter worth approximately $241,000. 7.96% of the stock is currently owned by institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.